SynthesisImmunity, inflammation and disease2023
Oral rehabilitation with dental implants in patients with systemic sclerosis: A systematic review.
Synthesis in Immunity, inflammation and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Implant-supported prosthetic rehabilitation after Ameloblastomas treatment: a systematic review.BMC oral health · 2023Pooled it
- Oral rehabilitation with dental implants in patients with systemic sclerosis: A systematic review.Immunity, inflammation and disease · 2023Pooled it
- Differential Outcomes of Dental Implant Osseointegration in Florid Cemento-Osseous Dysplasia: A Case Report.International medical case reports journal · 2026Article
- Orofacial Complications of the Connective Tissue Disease Systemic Sclerosis.Journal of dental research · 2024Review
- Are implant-based treatments considered viable for patients with focal or florid cemento-osseous dysplasia? A systematic review.Maxillofacial plastic and reconstructive surgery · 2024Review
- Complete Dental Implant Restoration in an Individual With Systemic Sclerosis and Microstomia: A Case Report.Case reports in dentistry · 2024Article
- Oral health and dental care challenges in scleroderma-perspectives of dentists, rheumatologists and patients.Rheumatology advances in practice · 2024Article
- Evaluation of Paxillin Expression in Epithelial Dysplasia, Oral Squamous Cell Carcinoma, Lichen Planus with and without Dysplasia, and Hyperkeratosis: A Retrospective Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2023Article
- Effect of inter-dental abutment distance on the impression accuracy of digital and conventional methods.Journal of medicine and life · 2023Article
- Cross Talk Between Cells and the Current Bioceramics in Bone Regeneration: A Comprehensive Review.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the influence of systemic sclerosis (SSc) on the survival rate of dental implants in SSc patients receiving implant-supported treatments.
methodsThe Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) Statement and the Cochrane Collaboration's guiding principles were followed during the study's execution. The data from three databases, PubMed, Google Scholar, and Scopus, available until January 2023, were used to compile the material for our research. Only English-language publications were submitted for this research and evaluated based on their titles, abstracts, and full texts. For performing a quality assessment, quality scores were calculated.
resultsThe total number of patients and implants studied were 37 and 153, respectively, all having had scleroderma. The patients' ages ranged from 28 to 77 years old, with a mean (SD) age of 58.16 (12.88). All the patients in the case reports and most in the case series study were female. The range of follow-up duration was from 1 to 10 years. In case report studies, the survival rate was 100%; in case series, it was 89.2%.
conclusionThe SSc status had no discernible impact on the implant survival rate. Implant-based treatments in SSc patients should not worsen the overall morbidity and should not conflict with systemic treatments. Before starting implant therapy, a thorough risk assessment is essential, though.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.